PK of nanoformulated cancer drugs in the brain


cOFM was successfully used to measure substance transport enhanced by nanocarriers across the blood-brain barrier

 

 

Challenge

The treatment of neurological diseases drugs requires the transport of drugs across the protective barrier of the brain – the blood brain barrier. The sponsor of this study was interested to test different formulations of a cancer drug regarding their efficiency to reach the intended target in the brain.

OFM Reference Project - cOFM PK of nanoformulated cancer drugs in the brain

Solution

A new nanoformulation for an existing brain cancer drug was compared with the established formulation regarding substance transport across the BBB. In a preclinical setup we used cOFM to measure substance concentrations in the brain.

 

Results

BBB intactness was confirmed 14 days after cOFM implantation by the integrity marker sodium fluorescein.

OFM results showed a significantly higher concentration of the nanoformulated drug in the brain tissue compared with the generic formulation of the drug.
 

 

Results are published in


Birngruber T, Raml R, Gladdines W, Gatschelhofer C, Gander E, Ghosh A, et al. Enhanced Doxorubicin Delivery to the Brain Administered Through Glutathione PEGylated Liposomal Doxorubicin (2B3-101) as Compared with Generic Caelyx,(®) /Doxil(®) -A Cerebral Open Flow Microperfusion Pilot Study. J Pharm Sci 2014;103:1945–8. doi:10.1002/jps.23994.​​​​​​​

 

Talk to our cOFM expert

Learn how OFM works and find out more about its individual applications for your drug development program

Arrange a meeting